GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alterity Therapeutics Ltd (ASX:ATH) » Definitions » Valuation Rank

Alterity Therapeutics (ASX:ATH) Valuation Rank


View and export this data going back to 2000. Start your Free Trial

What is Alterity Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Alterity Therapeutics Valuation Rank Related Terms

Thank you for viewing the detailed overview of Alterity Therapeutics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Alterity Therapeutics (ASX:ATH) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alterity Therapeutics Ltd (ASX:ATH) » Definitions » Valuation Rank
Comparable Companies
ASX:NOX ASX:IMC ASX:ACR ASX:CHM ASX:1AI ASX:ATX ASX:PTX ASX:PAB ASX:RAD ASX:BTC OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
ATHE:USA PBN:Germany
Address
350 Collins Street, Level 14, Melbourne, VIC, AUS, 3000
Website
https://www.alteritytherapeutics.com
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.